文献速递类风湿关节炎脊柱关节炎

托法替布减轻类风湿关节炎、银屑病关节炎或强直性脊柱炎患者疼痛的疗效

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
PubMed 文献 · RMD Open · 2020-01-01

该研究为随机对照试验的事后分析,纳入七项托法替布研究共3330例患者,评估托法替布5或10 mg每日两次对比安慰剂在类风湿关节炎、银屑病关节炎和强直性脊柱炎中的镇痛效果。结果显示,托法替布组在多个疼痛评估指标上较安慰剂组出现快速且持续的改善。

要点

  • 托法替布在RA和PsA患者中最早评估时间点即显示疼痛改善,并维持至第6个月。
  • 在AS患者中,托法替布组第12周时疼痛较安慰剂组改善。
  • 疼痛改善涉及多个患者报告结局指标,包括关节炎疼痛评估和健康调查问卷等。

核心结论

  • 托法替布在炎症性风湿肌肉骨骼疾病患者中与多个疼痛指标的快速且持续改善相关。

研究设计与样本

  • 研究为七项托法替布随机对照试验的事后分析,包括六项III期研究(四项RA、两项PsA)和一项II期研究(AS),共纳入3330例患者。

主要发现

  • 在RA和PsA人群中,托法替布治疗组较安慰剂组在最早评估时间点和第3个月观察到疼痛改善,并维持至第6个月。
  • 在AS人群中,托法替布组较安慰剂组在第12周观察到疼痛改善。

关键数值与推荐

  • 仅纳入接受托法替布5 mg或10 mg每日两次或安慰剂的患者。
  • 疼痛评估包括患者关节炎疼痛评估、SF-36v2第7题及躯体疼痛领域、ASQoL第9和14题、EQ-5D疼痛/不适维度及BASDAI第2和3题。
  • RA和PsA人群数据报告至第6个月(安慰剂至第3个月),AS人群报告至第12周。

临床怎么用

  • 对于RA、PsA或AS患者,托法替布可作为改善疼痛的治療选择之一,需结合患者既往治疗反应和疾病类型个体化决策。

局限性

  • 本研究为事后分析,仅纳入接受托法替布5或10 mg每日两次或安慰剂的患者,结果解释需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) in a post-hoc analysis of randomised controlled trials. METHODS: Data were collected from patients in seven tofacitinib studies: six phase III (four RA, two PsA) and one phase II study (AS), and grouped into five analysis populations based on rheumatic disease diagnosis and category of prior inadequate response (IR) to treatment: conventional synthetic disease-modifying antirheumatic drugs-IR (RA and PsA), tumour necrosis factor inhibitors-IR (RA and PsA), or non-steroidal anti-inflammatory drugs-IR (AS). Only patients who received tofacitinib 5 or 10 mg twice daily or placebo were included. Pain assessments included: Patient's Assessment of Arthritis Pain, Short-Form Health Survey 36v2 Question (Q)7 and Bodily Pain domain, Ankylosing Spondylitis Quality of Life Q9 and Q14, EuroQol Five Dimensions Pain/Discomfort dimension and Bath Ankylosing Spondylitis Disease Activity Index Q2 and Q3. Data were reported to month 6 (placebo to month 3) in the RA and PsA populations, and week 12 (tofacitinib and placebo) in the AS population. RESULTS: Overall, 3330 patients were included in this analysis. In the RA and PsA populations, pain improvements in tofacitinib-treated patients compared with placebo were observed at the earliest time point assessed and at month 3 (maintained to month 6). In the AS population, pain improvements compared with placebo were observed at week 12. CONCLUSION: Tofacitinib was associated with rapid and sustained improvements across multiple pain measures in patients with inflammatory rheumatic musculoskeletal diseases.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Ogdie A, de Vlam K, McInnes IB, et al. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. RMD Open. 2020. PMID: 32396519. doi:10.1136/rmdopen-2019-001042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。